Stocks Close Out Negative Week/September With Government Shutdown & Higher Rates In View – $ARKK $BRQS $INDP $NVDA $TSLA Rise!

Happy Saturday!

I hope that the world saw it your way this week.

As for the broad markets this week, the stock indices managed to selloff again overall except for the Nasdaq that eked out a meager gain. At the same time all indices closed out September overall significantly lower. The CBOE Volatility Index (^VIX) rose another 3.67% closing at $17.52 over the last 5 days as fears increased overall this week as the US government shutdown and the fed’s rising interest rates plagued investors and the markets. Oil prices did not help either as they closed at $90.91/bbl up 1% this week getting back to its rising ways now up 13.3% YTD. Interestingly, the yield curve closed with the the 2-yr yield moving lower to 5.o5% and the 10-yr note moving higher to 4.58%.

A number of macroeconomic reports hit the presses again this week leaving a bit of a mixed picture for the Fed to consume. On Tuesday, the July FHFA Housing Price Index report came in higher at .8%, the July S&P Case-Shiller Home Price Index report came in at .1%, & the September Consumer Confidence report clocked in lower at 103. Lastly, the August New Home Sales report came less than expected at 675k. On Wednesday, The weekly MBA Mortgage Applications Index report showed a 1.3% drop as purchase applications fell 1% & refinance applications moved lower by 2%. The Total durable goods orders report confirmed a .2% M/M rise in August. On Thursday, the Initial claims report for the week ending September 23 rising 2k to 204k, while continuing jobless claims for the week ending September 16 rose 12k to 1.67M. The 3rd estimate for Q2 GDP came in flat from at 2.1%, while the GDP Deflator was revised downward to 1.7%. On Friday, the Personal Income report showed a 4%M/M rise in August & Personal spending rose .4% M/M. The PCE Price Index also increased by .4% & the core PCE Price Index edged up .1% lower than expectations. The headline PCE Price Index moved up 3.5% just higher than July’s reading. The core PCE Price Index shoed down to 3.9% Y/Y. The Advanced Trade in Goods deficit report also confirmed a narrowing to $84.3B and down from $90.9B in August. The Wholesale inventories report confirmed a .1% move lower in August & the Retail inventories rose 1.1% in August. The Chicago PMI report confirmed a drop to 44.1 in September, while the final reading of the University of Michigan Consumer Sentiment Index report for September clocked in at 68.1.

At the end of the week, the Dow 30 closed at 33,508 (-1.3%) this week and is now up just 1.1% YTD. The S&P 500 closed at 4,288 (-.7%) for the week and is now up 11.7% YTD. The Nasdaq rose .1% for the week closing at 13,219 and is now up 26.3% YTD.

The Magnificent Seven had a mixed week with Tesla and Nvidia leading al. The crew performed as follows over the last 5-days: Alphabet (GOOG) closing at $131.85, +.46%, Amazon (AMZN) closing at $127.12, -1.55%, Apple (AAPL, $171.21, -2.05%), Meta Platforms (META) closing at $300.21, +.38%, Microsoft (MSFT) closing at $315.75, +.67%, NVIDIA (NVDA) closing at $434.99, +4.54% & Tesla (TSLA) closing at $250.22, +2.18%.

Curiously the small caps on the Russell 2000 showed some strength and closed at 1,785.10 (+.48%) for the week & is now up 1.35% YTD. The MicroCaps also moved lower this week as the iShares Micro-Cap ETF (IWC) closed at $100.10, -.24% this week & is now down 7.17% YTD. 

The U.S. Dollar Index also rose again this week from 105.58 to 106.20 this week.  

Bank stocks rose in general as the SPDR S&P Regional Banking ETF (KRE) moved up 1.48% over the last 5-days to close at $41.16 and is now down 28.89% YTD & the SPDR S&P Bank ETF (KBE) also moved up .82% over the last 5-days to close at $36.85.

The Biotech sector saw a somewhat positive week across the board.  The Nasdaq Biotechnology ETF (IBB) closed at $122.29, -.22% over the last 5-days and is now down 6.56% YTD, the NYSE ARCA Biotech Index (^BTK) closed at 5,014.80, +.06% over the last 5-days and is now down 5.04% YTD, & the SPDR S&P Biotech ETF (XBI) closed at $73.02, +.08% over the last 5-days, & is now down 12.02% YTD. The 52-week range is is now $71.59-$92.60 and continues to get tighter.

Cathie Wood’s ARK Innovation ETF (ARKK) closed at $39.67, +2.19% over the last 5-days and is up 24.26% YTD.   

The iShares U.S. Healthcare ETF (IYH) closed at $270.07, -1.39% over the last 5-days and is now down 4.81% YTD.   

From the world of cryptocurrency, Bitcoin (BTC) moved to $26,903.91 up 2.30% over the course of the last 5-days at the time of the completion of this message.

Gold prices closed at $1,858, -$70/oz over the last 5-days. Silver prices closed at $22.44, -$1.22/oz over the last 5-days. The Global X Silver ETF (SIL) closed at $23.90, -4.63% over the last 5-days.

VP Watchlist Updates

Lantern (LTRN), closed at $3.41, -6.65% over the last 5-days, but rose to $3.93, +15.25% in the aftermarket on Friday. Lantern is an Artificial Intelligence (AI) firm that is transforming the cost, pace, and timeline of oncology drug discovery and development and specifically is developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning (“ML”) platform with multiple clinical stage drug programs.

On September 25, Lantern announced the dosing of the first patient in the Phase 1 clinical trial evaluating Lantern’s investigational new drug LP-184 in patients with advanced solid tumors. LP-184 is being studied in a first-in-human Phase 1 clinical trial, having been developed with guidance from Lantern’s AI Platform, RADR®, as a potential therapy for a wide range of advanced solid tumors. LP-184 is one of two molecules in Lantern’s synthetic-lethal franchise that has been shown to have anti-cancer activity in tumors with DNA damage repair deficiency. Lantern estimates that LP-184 has a global aggregate market potential of approximately $11-13 billion, consisting of $6-7 billion for solid tumors and $5-6 billion for CNS cancers. To learn more click here. 

On September 18, Lantern announced that the United States Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for LP-284. LP-284 is being developed for the treatment of relapsed or refractory non-Hodgkin’s lymphoma (NHL), including mantle cell lymphoma (MCL) and double hit lymphoma (DHL) and other high-grade B-cell lymphomas (HGBL). Lantern expects to commence enrollment of patients for the first-in-human Phase 1 trial for LP-284 during the fourth quarter of 2023. Lantern estimates that LP-284 can have the potential to improve outcomes for 40,000 to 80,000 patients with blood cancers annually, with a global annual market potential of $4 Billion USD.

 

Panna Sharma is the President, CEO, and Board Member of Lantern Pharma Inc.

“This is now our second novel drug candidate to receive IND clearance from the FDA in the past 100 days, further validating our approach of leveraging AI and machine learning to accelerate the development of our pipeline. LP-284 holds blockbuster potential, and we have been able to expedite its journey from a concept to a first-in-human clinical trial in a highly efficient and cost-effective manner – less than 2.5 years and under approximately $2.7 million – underscoring the power and potential of our AI platform RADR® to accelerate oncology drug discovery and development. RADR® was used to unravel the mechanism of action of LP-284, prioritize its cancer indications, and generate machine-learning biomarker signatures that may be pivotal in selecting patients for future phases of the clinical trials. Our success-to-date with LP-284 reaffirms our commitment to harnessing the power of AI to transform cancer treatment and save lives,” stated Panna Sharma, Lantern’s President and CEO.

On September 8, Lantern’s Chief Executive Officer, Panna Sharma, delivered a presentation titled “How Artificial Intelligence Is Crushing Drug Discovery Times & Costs In Cancer” at a Tribe Public CEO Presentation & Q&A Event. The Event video is now published at the Tribe Public YouTube Channel that you may view now by clicking here.

On August 31, Lantern announced that it will present positive data highlighting the anti-tumor potency of its drug candidate LP-284 for non-Hodgkin’s lymphoma (NHL) at the Society of Hematologic Oncology (SOHO) Eleventh Annual Meeting occurring on Sept. 6 – 9, 2023, at the George R. Brown Convention Center in Houston, Texas. LP-284 is a small molecule with a synthetically lethal mechanism of action that preferentially damages cancer cells.. Lantern is developing LP-284 for the treatment of relapsed or refractory NHL, including Mantle Cell Lymphoma and Double Hit Lymphomas. Lantern expects to initiate Phase 1 clinical trials for LP-284 during Q4 of 2023. Lantern’s LP-284 program has been accelerated and de-risked using AI insights and biological modeling powered by RADR®. Lantern has been able to advance LP-284 from initial RADR® insights regarding anti-cancer activity and potential mechanisms of action in hematological cancers, to selection of specific subtypes of lymphomas with superior response, to late-stage IND enabling studies, and initial design of first in human clinical trials in less than two years.

Details of the poster presentation are listed below and can be found on the SOHO website. A full version of the poster will be available on Lantern’s website on September 11, 2023.

Title: LP-284 – Targeting Homologous Recombination Deficiencies in B-Cell Non-Hodgkin’s Lymphomas with the Novel Anti-Tumor Small Molecule LP-284
Date and Time: September 6, 2023, 6:00pm CT
Poster Number: ABCL-180
Presenter: Jianli Zhou, Ph.D., Lantern Pharma

On August 28, Lantern announced a substantial increase in the power and capabilities of RADR® focused on improving the drug development process for immune checkpoint inhibitors (ICIs). These capabilities are expected to address the multiple challenges facing the increased usage of ICIs in cancer therapy. Since gaining regulatory approval in 2011, ICIs have improved the lives of tens of thousands of cancer patients as either monotherapies, and more recently, in combination regimens with other therapies. The success of ICIs has resulted in multiple competing ICI molecules, often from the same class, in overlapping cancer indications. Additionally, recent clinical trial failures reveal headwinds to the desired expansion of ICIs for a broader range of cancers and patient groups. Currently, there are over 5,200 ongoing clinical trials involving ICIs, many of these lacking adequate biomarker strategies or guidance from AI enabled approaches to optimize the selection of patient responder populations. In a recent study presented at the 2023 ASCO meeting, RADR’s® algorithms demonstrated an 88% accuracy rate in predicting which melanoma (skin cancer) patients exhibiting resistance to anti-PD1 therapy will respond to Elraglusib, a GSK-3ϐ inhibitor being developed by Actuate Therapeutics, which previously entered into a multi-year research and development collaboration with Lantern Pharma to leverage the RADR® platform. The continued growth of ICIs, especially the approval of new ICIs, will be predicated on: 1) efficiently identifying new biomarker or molecular signatures for optimal patient selection, stratification, and management, and 2) rapidly developing combination regimens that overcome treatment challenges facing current and emerging solid and hematological cancer indications. Lantern’s latest RADR® AI developments will focus on addressing these challenges by building automated and highly scalable computational analytics to generate clinically relevant tumor-specific and tumor-agnostic molecular signatures to guide the identification and development of drug combinations that can prolong ICI durability of response and improve patient survival. These developments will leverage RADR® to uncover molecular drivers of response and resistance influencing ICI treatment outcomes by coupling pathway and network-based analytics with the simultaneous screening of millions of targets from complex clinical and biological data sets. This capability will be powered by tens of billions of new data points from immunotherapy and checkpoint inhibitor studies that Lantern has begun to add to its RADR® platform.

Lantern plans to deploy its new RADR® ICI predictive module with biopharma partners and to identify potential combinatorial strategies for LP-184 and LP-284, the first of Lantern’s drug candidates developed internally with the assistance of the RADR® AI platform. The ICI market is projected to reach $67.8 billion in annual sales by 2025, according to GlobalData, with future growth dependent on approvals from precision-based approaches guiding the development and positioning of new combination therapies.

On August 14, Lantern announced that it has received a notice of allowance from the United States Patent and Trademark Office (USPTO) covering a method of treatment for Atypical Teratoid Rhabdoid Tumor (ATRT) using LP-184, an aggressive and rapidly growing form of cancer of the central nervous system (CNS). LP-184 is the first of Lantern’s drug candidates developed by leveraging Lantern’s AI and ML platform, RADR®, to advance to a first-in-human Phase 1 basket trial. Lantern has rapidly advanced the clinical development of LP-184, activated the initial clinical trial sites, and has begun screening patients. Indications for the LP-184 trial are anticipated to include relapsed/refractory advanced pancreatic cancer, glioblastoma (GBM), brain metastases (brain mets), and multiple other recurring, advanced solid tumors with DNA damage response deficiencies. The dosage and safety data obtained in the Phase 1 trial will be used to advance the CNS indications, including ATRT, for a future Phase 2 trial to be sponsored by Lantern’s wholly-owned subsidiary, Starlight Therapeutics Inc. Globally, the aggregate annual market potential of LP-184’s target indications is estimated to be approximately $10+ billion, consisting of $5+ billion for CNS cancers and $6+ billion for other solid tumors. The U.S. Food and Drug Administration (FDA) has previously granted LP-184 Rare Pediatric Disease Designation and Orphan Drug Designation (ODD) for the treatment of pediatric patients with ATRT. The FDA has also previously granted LP-184 ODD for the treatment of pancreatic cancer and for the treatment of malignant glioma, including GBM. A notice of allowance is issued after the USPTO determines that the prosecution on the merits of a patent has been completed and grants the patent upon payment of the patent issuance fee. Additional corresponding patent applications are pending in Europe, Japan, Canada, and Australia.

Shares of Indaptus Therapeutics, Inc. (Nasdaq: INDP) closed at $2.755, +1.66% over the last 5-days and rose to $2.80 up 2.94% in the aftermarket on Friday. INDP stocks is also up 90% YTD.

Indaptus is a company with the ability to harness both the body’s innate and adaptive immune responses, believes that they are uniquely positioned to revolutionize the treatment of cancer and certain infectious diseases. Indaptus Therapeutics has evolved from more than a century of immunotherapy advances. The Company’s novel approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and pathways and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system-activating signals that can be administered safely intravenously (i.v.). Indaptus’ patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria producing a multiple Toll-like receptor (TLR), Nucleotide oligomerization domain (Nod)-like receptor (NLR) and Stimulator of interferon genes (STING) agonist Decoy platform. The products are designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cells and pathways of innate and adaptive immunity. Decoy products represent an antigen-agnostic technology that have produced single-agent activity against metastatic pancreatic and orthotopic colorectal carcinomas, single agent eradication of established antigen-expressing breast carcinoma, as well as combination-mediated eradication of established hepatocellular carcinomas and non-Hodgkin’s lymphomas in standard pre-clinical models, including syngeneic mouse tumors and human tumor xenografts.

In pre-clinical studies tumor eradication was observed with Decoy products in combination with anti-PD-1 checkpoint therapy, low-dose chemotherapy, a non-steroidal anti-inflammatory drug, or an approved, targeted antibody. Combination-based tumor eradication in pre-clinical models produced innate and adaptive immunological memory, involved activation of both innate and adaptive immune cells, and was associated with induction of innate and adaptive immune pathways in tumors after only one i.v. dose of Decoy product, with associated “cold” to “hot” tumor inflammation signature transition. IND-enabling, nonclinical toxicology studies demonstrated safe i.v. administration without sustained induction of hallmark biomarkers of cytokine release syndromes, possibly due to passive targeting to liver, spleen, and tumor, followed by rapid elimination of the product. Indaptus’ Decoy products have also produced significant single agent activity against chronic hepatitis B virus (HBV) and chronic human immunodeficiency virus (HIV) infections in pre-clinical models.

On Sept. 19, Indaptus announced dosing of the first patient in the second cohort of patients to receive a single dose of Decoy20 in the INDP-D101 trial. This cohort dose is a dose reduction from the previous cohort based on the significant pharmacodynamic effect seen with the first cohort and anticipated optimal Decoy20 safety profile for both weekly dosing and combination approaches. Dr. Roger Waltzman, Indaptus’ Chief Medical Officer stated, “This cohort is important to the development of Decoy20 as it may provide sufficient data for us to move Decoy20 to a multi-dosing regimen. To date, we have seen positive signs of an immune response with an anticipated adverse effect profile, and we look forward to seeing whether this lower dose provides similar evidence of increased cytokines that can trigger both innate and adaptive immune responses.” Jeffrey Meckler, Chief Executive Officer stated,“We continue to be encouraged by the initial results of the first cohort and look forward to progressing into the multi-dosing regimen as soon as we have enough data. The study’s objectives are to assess the safety and tolerability of Decoy20, to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D), as well as to assess Decoy20 pharmacokinetics (PK), pharmacodynamics and clinical activity. The Phase 1 study was initiated with a single dose escalation, which is planned to be followed by an expansion with continuous weekly administration of Decoy20. The study is enrolling patients with advanced/metastatic solid tumors, who have exhausted approved treatment options. More information can be found at www.clinicaltrials.gov.

On August 14, Indaptus announced financial results for the second quarter ended June 30, 2023 and provided a corporate update.

Jeffrey Meckler, CEO, Indaptus Therapuetics, Inc. (NASDAQ: INDP)

Jeffrey Meckler, Chief Executive Officer of Indaptus stated, “We have recently announced the completion of the first cohort of patients in our INDP-D101 trial evaluating Decoy20 for the treatment of solid tumors and receipt of authorization from the Safety Review Committee to advance into the second cohort. As previously announced, we are pleased to observe evidence of immune activation, along with short-lived adverse events consistent with Decoy20’s mechanism of action. We continue to analyze the data generated and anticipate that the data from the dose finding studies will guide the selection for the recommended Phase 2 dose for subsequent multi-dosing and combination studies, which are planned for 2024. An additional recent accomplishment is the appointment of industry veteran, Roger Waltzman, M.D., as our Chief Medical Officer. We anticipate benefiting from his expertise as we continue our Phase 1 trial and further develop the Decoy platform. In the meantime, we are prudently managing our cash position.”

Recent Corporate Highlights:

• The Company announced the completion of the first cohort of its INDP-D101 trial and receipt of authorization from its Safety Review Committee to proceed into the second cohort of the Phase 1 trial.
• A compound from the Company’s Decoy platform was presented in a poster titled, “A systemically administered killed bacteria-based multiple immune receptor agonist for pulsed anti-tumor immunotherapy,” at the American Association for Cancer Research Conference 2023. The poster highlighted that Decoy10 demonstrated 90% reduction of LPS-endotoxin activity and use of 100% killed, non-pathogenic bacteria.
• The Company’s Chief Scientific Officer, Michael Newman, Ph.D., was named Chair for two of the three days of the 4th STING & TLR-Targeting Therapies Summit held in Boston from May 9 to 11, where he was also a featured speaker.
• The Company received patent allowances for its Decoy immunotherapy platform in Brazil and India. The Indian patent allowance brought the number of countries in which the Company holds patent protection to 32.
• Roger Waltzman, M.D. was appointed the Chief Medical Officer of Indaptus, effective August 7, 2023.

Learn more about Indaptus Therapeutics (NASDAQ: INDP) at the VP Watchlist page by clicking here.

Thanks again for your attention this week. Please continue to share your thoughts, questions, & ideas as we move forward. 

In the meantime, please enjoy the balance of the weekly newsletter’s videos, quotes, updates and let’s find ways to crush it again as we move forward!

Investing & Inspiration

1. “The Universe is under no obligation to make sense to you.” – Neil deGrasse Tyson
2. “Care and diligence bring luck.” – Thomas Fuller
3. “Nobody made a greater mistake than he who did nothing because he could do only a little.” – Edmund Burke
4. “A man who is a master of patience is master of everything else.” – George Savile
5. “Once you replace negative thoughts with positive ones, you’ll start having positive results.” – Willie Nelson
6. “Endurance is nobler than strength, and patience than beauty.” – John Ruskin
7. “Act as if what you do makes a difference. It does.” – William James
8. “Let us be grateful to people who make us happy, they are the charming gardeners who make our souls blossom.” –  Marcel Proust
9. “Strength and growth come only through continuous effort and struggle.” – Napoleon Hill
10. “Science may never come up with a better office communication system than the coffee break.” – Earl Wilson
11. “If everyone is moving forward together, then success takes care of itself.” – Henry Ford
12. “Hope is like the sun, which, as we journey toward it, casts the shadow of our burden behind us.”– Samuel Smiles
13. “Patriotism is supporting your country all the time, and your government when it deserves it.” – Mark Twain
14. “What would life be if we had no courage to attempt anything?” – Vincent Van Gogh
15. “The biggest risk is not taking any risk… In a world that is changing really quickly, the only strategy that is guaranteed to fail is not taking risks.” – Mark Zuckerberg
16. “Our lives improve only when we take chances – and the first and most difficult risk we can take is to be honest with ourselves.” – Walter Anderson
17. “Action is the foundational key to all success.” – Pablo Picasso
18. “Success is never final, failure is never fatal. It’s courage that counts.” – John Wooden
19. “Innovation distinguishes between a leader and a follower.” – Steve Jobs
20. “All the art of living lies in a fine mingling of letting go and holding on.” – Havelock Ellis
21. “The size of your success is measured by the strength of your desire; the size of your dream; and how you handle disappointment along the way.” – Robert Kiyosaki
22. “O, wind, if winter comes, can spring be far behind?” – Percy Bysshe Shelley
23. “Patience is a virtue, and I’m learning patience. It’s a tough lesson.” – Elon Musk
24. “Be true to your work, your word, and your friend.” – John Boyle O’Reilly
25. “Believe in yourself! Have faith in your abilities! Without a humble but reasonable confidence in your own powers you cannot be successful or happy.” – Norman Vincent Peale
26. “Surprise is the greatest gift which life can grant us.” – Boris Pasternak
27. “Logic will get you from A to B. Imagination will take you everywhere.” – Albert Einstein
28. “It is the fight alone that pleases us, not the victory.” – Blaise Pascal
29. “Do exactly what you would do if you felt most secure.” – Meister Eckhart
30. “Life lived for tomorrow will always be just a day away from being realized.” – Leo Buscaglia
31. “Wisdom is oftentimes nearer when we stoop than when we soar.” – Wordsworth
32. “Take chances, make mistakes. That’s how you grow. Pain nourishes your courage. You have to fail in order to practice being brave.” – Mary Tyler Moore
33. “A single twig breaks, but the bundle of twigs is strong.” – Tecumseh
34. “If one does not know to which port one is sailing, no wind is favorable.” – Lucius Annaeus Seneca
35. “There is little that can withstand a man who can conquer himself.” – Louis XIV
36. “The limits of the possible can only be defined by going beyond them into the impossible.” – Arthur C. Clarke
37. “Be faithful in small things because it is in them that your strength lies.” – Mother Teresa
38. “The future rewards those who press on. I don’t have time to feel sorry for myself. I don’t have time to complain. I’m going to press on.” – Barack Obama
39. “By three methods we may learn wisdom: First, by reflection, which is noblest; Second, by imitation, which is easiest; and third by experience, which is the bitterest.” – Confucius
40. “No man was ever wise by chance.” – Lucius Annaeus Seneca
41. “Progress is man’s ability to complicate simplicity.” – Thor Heyerdahl
42. “It is not in the stars to hold our destiny but in ourselves.” – William Shakespeare

43. “It does not matter how slowly you go as long as you do not stop.” – Confucius

44. “I want to put a ding in the universe.” – Steve Jobs

45. “Research is creating new knowledge.” – Neil Armstrong

46. “The reward for work well done is the opportunity to do more.” – Jonas Salk
47. “Man is a creative retrospection of nature upon itself.” – Karl Wilhelm Friedrich Schlegel
48. “There’s something about taking a plow and breaking new ground. It gives you energy.” – Ken Kesey

49. “Success seems to be largely a matter of hanging on after others have let go.” – William Feather

50. “The essential conditions of everything you do must be choice, love, passion.” – Nadia Boulanger

51. “More business is lost every year through neglect than through any other cause.” – Rose Kennedy

52. “Give me a lever long enough and a fulcrum on which to place it, and I shall move the world.” – Archimedes

53. “A person who won’t read has no advantage over one who can’t read.” – Mark Twain

54. “The best way out is always through.” – Robert Frost

55. “Start by doing what’s necessary; then do what’s possible; and suddenly you are doing the impossible.” – Francis of Assisi

56. “Without labor nothing prospers.” – Sophocles

57. “Intellectuals solve problems, geniuses prevent them.” – Albert Einstein

58. “This is the precept by which I have lived: Prepare for the worst; expect the best; and take what comes.” – Hannah Arendt

59. “The best and most beautiful things in the world cannot be seen or even touched – they must be felt with the heart.” – Helen Keller

60. “He who is brave is free.” – Lucius Annaeus Seneca

61. “When something is important enough, you do it even if the odds are not in your favor.” – Elon Musk

62. “I choose a block of marble and chop off whatever I don’t need.” – Auguste Rodin

63. “Hope is the only bee that makes honey without flowers.” – Robert Green Ingersoll

64. “He who knows that enough is enough will always have enough.” – Lao Tzu

65. “Plans to protect air and water, wilderness and wildlife are in fact plans to protect man.” – Stewart Udall

66. “In order to carry a positive action we must develop here a positive vision.” – Dalai Lama

67. “A hero is someone who understands the responsibility that comes with his freedom.” – Bob Dylan
68. “Inflation destroys savings, impedes planning, and discourages investment. That means less productivity and a lower standard of living.” – Kevin Brady
69. “If we give something positive to others, it will return to us. If we give negative, that negativity will be returned.” – Allu Arjun
70. “A good plan violently executed now is better than a perfect plan executed next week.” ~ George S. Patton
71. “You must do the things you think you cannot do.”- Eleanor Roosevelt
72. “Success is dependent on effort.” – Sophocles
73. “Nobody who ever gave his best regretted it.” – George Halas
74. “Lots of people want to ride with you in the limo, but what you want is someone who will take the bus with you when the limo breaks down.” ~ Oprah Winfrey
75. “And when I breathed, my breath was lightning.” – Black Elk
76. “Moderation is the silken string running through the pearl chain of all virtues.” – Joseph Hall
77. “You are the sum total of everything you’ve ever seen, heard, eaten, smelled, been told, forgot – it’s all there. Everything influences each of us, and because of that I try to make sure that my experiences are positive.” – Maya Angelou
78. “If you want a guarantee, buy a toaster.” – Clint Eastwood
79. “We are an impossibility in an impossible universe.” – Ray Bradbury
80. “If you think in terms of a year, plant a seed; if in terms of ten years, plant trees; if in terms of 100 years, teach the people.” – Confucius
81. “I’d rather attempt to do something great and fail than to attempt to do nothing and succeed.” – Robert H. Schuller
82. “Do your little bit of good where you are; it’s those little bits of good put together that overwhelm the world.” Desmond Tutu
83. “It takes considerable knowledge just to realize the extent of your own ignorance.” – Thomas Sowell
84. “Do not dwell in the past, do not dream of the future, concentrate the mind on the present moment.” – Buddha”
85. Surprise is the greatest gift which life can grant us.” –  Boris Pasternak
86. “Trust in dreams, for in them is hidden the gate to eternity.” – Khalil Gibran 
87. “Always be yourself, express yourself, have faith in yourself, do not go out and look for a successful personality and duplicate it.” – Bruce Lee
88. “All life is an experiment. The more experiments you make the better.” – Ralph Waldo Emerson
89. “There are no secrets to success. It is the result of preparation, hard work, and learning from failure.” –  Colin Powell
90. “There is more to life than increasing its speed.” – Mahatma Gandhi
91. “Your attitude is like a box of crayons that color your world. Constantly color your picture gray, and your picture will always be bleak. Try adding some bright colors to the picture by including humor, and your picture begins to lighten up.” – Allen Klein
92. “Definiteness of purpose is the starting point of all achievement.” – W. Clement Stone
93. “Success usually comes to those who are too busy to be looking for it.” – Henry David Thoreau
94. “In matters of truth and justice, there is no difference between large and small problems, for issues concerning the treatment of people are all the same.” – Albert Einstein
95. “Life is too short for long-term grudges.” – Elon Musk
96. “There cannot be a crisis next week. My schedule is already full.” – Henry Kissinger
97. “Success consists of getting up just one more time than you fall.” – Oliver Goldsmith
98. “The Earth is the cradle of humanity, but mankind cannot stay in the cradle forever.” – Konstantin Tsiolkovsky
99. “Ours is a world of nuclear giants and ethical infants. We know more about war that we know about peace, more about killing that we know about living.” – Omar N. Bradley
100. “Beauty surrounds us, but usually we need to be walking in a garden to know it.” – Rumi
101. “But man is not made for defeat. A man can be destroyed but not defeated.” – Ernest Hemingway
102. “Don’t watch the clock; do what it does. Keep going.” – Sam Levenson
103. “Let there be work, bread, water and salt for all.” – Nelson Mandela
104. “The social object of skilled investment should be to defeat the dark forces of time and ignorance which envelope our future.” – John Maynard Keynes
105. “A successful society is characterized by a rising living standard for its population, increasing investment in factories and basic infrastructure, and the generation of additional surplus, which is invested in generating new discoveries in science and technology.” – Robert Trout
106. “I know not with what weapons World War III will be fought, but World War IV will be fought with sticks and stones.” – Albert Einstein
107. “It is the fight alone that pleases us, not the victory.” – Blaise Pascal
108. “If you can’t describe what you are doing as a process, you don’t know what you’re doing.” – W. Edwards Deming
109. “Never interrupt your enemy when he is making a mistake.” – Napoleon Bonaparte
110. “Be sure you put your feet in the right place, then stand firm.” – Abraham Lincoln
111. “Without investment there will not be growth, and without growth there will not be employment.” – Muhtar Kent
112. “You have to do your own growing no matter how tall your grandfather was.” – Abraham Lincoln
113. “Victory has a thousand fathers, but defeat is an orphan.” – John F. Kennedy
114. “Delete the negative; accentuate the positive!” – Donna Karan
115. “It’s crazy how fast time flies and how things progress.” – Nathan Chen
116. “The world is a dangerous place to live; not because of the people who are evil, but because of the people who don’t do anything about it.” – Albert Einstein
117. “Life isn’t about finding yourself. Life is about creating yourself.” – George Bernard Shaw
118. “Everything has beauty, but not everyone sees it.” – Confucius
119. “A man must be big enough to admit his mistakes, smart enough to profit from them, and strong enough to correct them.” – John C. Maxwell
120. “Walking with a friend in the dark is better than walking alone in the light.” – Helen Keller
121. “A man who dares to waste one hour of time has not discovered the value of life.” – Charles Darwin
122. “The greater danger for most of us lies not in setting our aim too high and falling short; but in setting our aim too low, and achieving our mark.” – Michelangelo
123. “Progress is man’s ability to complicate simplicity.” – Thor Heyerdahl
124. “I like to encourage people to realize that any action is a good action if it’s proactive and there is positive intent behind it.” – Michael J. Fox
125. “Nothing is impossible, the word itself says ‘I’m possible’!” – Audrey Hepburn
126. “But investment in space stimulates society, it stimulates it economically, it stimulates it intellectually, and it gives us all passion.” – Bill Nye
127. “Bitcoin, in the short or even long term, may turn out be a good investment in the same way that anything that is rare can be considered valuable. Like baseball cards. Or a Picasso.” – Andrew Ross Sorkin
128. “Life is a tragedy when seen in close-up, but a comedy in long-shot.” – Charlie Chaplin
129. “No matter what you’re going through, there’s a light at the end of the tunnel and it may seem hard to get to it but you can do it and just keep working towards it and you’ll find the positive side of things.” – Demi Lovato
130. “Infrastructure investment in science is an investment in jobs, in health, in economic growth and environmental solutions.” – Oren Etzioni
131. “Educating our children and giving them the skills they need to compete in a global economy is a smart investment in our country’s future.” – Sheldon Whitehouse
132. “Know thy self, know thy enemy. A thousand battles, a thousand victories.” – Sun Tzu
133. “If one does not know to which port one is sailing, no wind is favorable.” – Lucius Annaeus Seneca
134. “Beware of missing chances; otherwise it may be altogether too late some day.” – Franz Liszt
135. “The sofa is a really important investment for anybody, and I don’t mean financially. You need to find a really great sofa that can transition with you, and you can build from there.” – Jeremiah Brent
136. “There is no investment you can make which will pay you so well as the effort to scatter sunshine and good cheer through your establishment.” – Orison Swett Marden
137. “Nothing in life is to be feared, it is only to be understood. Now is the time to understand more, so that we may fear less.” – Marie Curie
138. “There is little that can withstand a man who can conquer himself.” – Louis XIV
139. “In tennis, you strike a ball just after the rebound for the fastest return. It’s the same with investment.” – Masayoshi Son
140. “A camel makes an elephant feel like a jet plane.” – Jackie Kennedy
141. “The advance of technology is based on making it fit in so that you don’t really even notice it, so it’s part of everyday life.” – Bill Gates
142. “Success depends upon previous preparation, and without such preparation there is sure to be failure.” – Confucius, Chinese 
143. “Coming together is a beginning; keeping together is progress; working together is success.” – Edward Everett Hale
144. “Never do anything against conscience even if the state demands it.”– Albert Einstein
145. “Education is not only a ladder of opportunity, but it is also an investment in our future.” – Ed Markey
146. “The true measure of a man is how he treats someone who can do him absolutely no good.” – Samuel Johnson
147. “In my view, the biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital. Not only is the mere drop in stock prices not risk, but it is an opportunity. Where else do you look for cheap stocks?” – Li Lu
148. “A successful society is characterized by a rising living standard for its population, increasing investment in factories and basic infrastructure, and the generation of additional surplus, which is invested in generating new discoveries in science and technology.” – Robert Trout
149. “The best preparation for tomorrow is doing your best today.” – H. Jackson Brown, Jr.
150. “Friendship marks a life even more deeply than love. Love risks degenerating into obsession, friendship is never anything but sharing.” – Elie Wiesel
151. “Investing in women’s lives is an investment in sustainable development, in human rights, in future generations – and consequently in our own long-term national interests.” – Liya Kebede
152. “Success isn’t measured by money or power or social rank. Success is measured by your discipline and inner peace.” – Mike Ditka
153. “No matter how many goals you have achieved, you must set your sights on a higher one.” – Jessica Savitch 
154. “Start where you are. Use what you have. Do what you can.”– Arthur Ashe
155. “The secret of getting ahead is getting started.” – Mark Twain
156. “The amount of work and the amount of both physical and emotional investment it takes to get to the top.” – Drew Bledsoe